AI-driven Structure-enabled Antiviral Platform (ASAP)

The ASAP AViDD Center is an international consortium dedicated to the development of novel chemical assets that have antiviral activity against three target viral families (coronaviruses, flaviviruses, and picornaviruses). ASAP adopts a state-of-the-art structure-enabled paradigm capable of leveraging recent advances in AI/ML and computational chemistry in identifying, enabling, and prosecuting discovery campaigns against novel viral targets

ASAP uses artificial intelligence and computational chemistry to accelerate structure-based open science antiviral drug discovery and deliver oral antivirals for pandemics with the goal of global, equitable, and affordable access.

We are involved in creating Target Enabling Packages (TEPs), which are complete data packages needed to enable structure-based drug discovery against an antiviral target. Pioneered by the Structural Genomics Consortium, each TEP contains relevant protein constructs and plasmid resources for one or more viral family members, protein expression and purification protocols, crystallization conditions, structures from an X-ray fragment screen at the Diamond Light Source XChem facility, small molecule hits, and biochemical assay protocols with at least one validated inhibitor with quantifiable activity.

Our collaborators:

More information can be found at https://asapdiscovery.org/